Q-omics provides the consensus-scored UNC119 profile across patient tissues and cancer cell-line models. UNC119 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UNC119 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, UNC119 RNA expression shows 18,146 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, HNSC, and LIHC as cancer lineages where UNC119 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC119 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC119 survival associations across molecular data types. UNC119 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC119 RNA expression–survival associations across cancer types. High UNC119 expression shows unfavorable associations in KIRC, KICH, MESO and SKCM, but favorable associations in PAAD and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UNC119 RNA expression.
This table summarizes UNC119 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UNC119. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC119 shows higher tumor expression in HNSC, BLCA, COAD, LUAD, LUSC and KIRP. The HNSC box plot shows higher UNC119 RNA expression in tumor versus normal tissue (log2 FC = +1.279, t-test p < 0.001).
This table shows molecular features associated with UNC119 in patient tissues and cancer cell lines. In patient samples, UNC119 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, UNC119 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
